Thus, PXR pharmacological activation is considered a potential tool to treat inflammatory bowel disease and even sepsis [124,127], in which PXR agonists, including HPF, ginsenosides [131] and other natural compounds [128], would have the additional advantage of counterbalancing repression of the P450 drug metabolizing system determined by the high circulating cytokine levels [132]. Here, NR1I2 is linked to inflammatory bowel disease.